Start date: 01 January 2020
End date: 30 June 2025
The project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome antimicrobial resistance in pneumonia. The research focuses on the unique immunomodulator flagellin that enhances airway epithelial innate immune defences, and the development of airway-specific aerosol delivery by nebulisation. FAIR's main objectives include optimisation of nebulisation and demonstration of flagellin-associated enhancement of the antibiotic response, as well as obtaining pharmacokinetics and pharmacodynamics models for clinical validation and assessing flagellin nebulisation safety in a Phase I clinical trial.
Scientific coordinator of the project: Jean-Claude Sirard